Percutaneous Coronary Interventions Market to Surpass $8 Billion by 2022

The global market for percutaneous coronary interventions, which covers coronary stents, percutaneous transluminal coronary angioplasty (PTCA) balloons, and PTCA drug-eluting balloons, is forecast to grow from $6.3 billion in 2015 to $8.1 billion by 2022, at a compound annual growth rate of 3.5 percent, according to research and consulting firm GlobalData.
 
The company’s latest report states that this steady growth, which covers the market in 39 countries, will be driven by rising disease prevalence and improving technologies. Over the years, an array of bare metal stents (BMS) and drug-eluting stents (DES) have been developed, featuring innovative materials, designs, structures, coatings, and drug-elution components.
 
“The development and optimization of DESes has become a primary focus for many stent manufacturers, where they utilize the BMSes they have developed as the platform and foundation for their DESes,” explained Premdharan Meyyan, GlobalData’s Analyst covering the medical device market. “These innovations in technology aim to ensure high radial strength and flexibility, low elastic recoil, optimal vessel coverage, minimal foreshortening, and rapid strut endothelialization.”
 
The coronary stents market is vast and dynamic, and is saturated with numerous players worldwide. The competitive landscape consists of large, mid-size, and small companies that have developed different types of coronary stents to target various indications. However, a few key players dominate the market, including Abbott Vascular, Medtronic plc, and Boston Scientific Corp.
 
“As the next generation of DESes and BASes enter the market, the current key players will need to retain and acquire market share by improving the clinical performance of their existing products. In addition, they will need to expand into or increase their presence in emerging markets in order to take revenue away from their competitors in the future,” Meyyan said.
 
In terms of regional variations in the coronary interventions space, the United States, France, Germany, Italy, Spain, and the United Kingdom markets are expected to slowly decline in value in the future. As medical costs continue to rise, healthcare providers are implementing cost-containment policies and ‘appropriateness criteria’ to reduce costs and overstenting.
 
“Unlike in the West, the coronary stents markets in the Asia-Pacific and South American regions are expected to demonstrate steady growth in the future. The APAC countries, including Japan, China, and India, have diverse populations, ethnicities, and clinical practices. Most device manufacturers regard Japan and China as their chief targets, due to their economic growth, pricing structure, and vast populations,” Meyyan concluded.